ATE353325T1 - 4-heterocyclylsulfonamidyl-6-methoxy-5-(2-metho y-phenoxy)-2-pyridyl-pyrimidin derivate, deren herstellung und deren verwendung als endothelin rezeptor antagonisten - Google Patents

4-heterocyclylsulfonamidyl-6-methoxy-5-(2-metho y-phenoxy)-2-pyridyl-pyrimidin derivate, deren herstellung und deren verwendung als endothelin rezeptor antagonisten

Info

Publication number
ATE353325T1
ATE353325T1 AT00909263T AT00909263T ATE353325T1 AT E353325 T1 ATE353325 T1 AT E353325T1 AT 00909263 T AT00909263 T AT 00909263T AT 00909263 T AT00909263 T AT 00909263T AT E353325 T1 ATE353325 T1 AT E353325T1
Authority
AT
Austria
Prior art keywords
heterocyclylsulfonamidyl
metho
phenoxy
pyridyl
methoxy
Prior art date
Application number
AT00909263T
Other languages
English (en)
Inventor
Volker Breu
Philippe Coassolo
Werner Neidhart
Sebastien Roux
Peter Weiss
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE353325T1 publication Critical patent/ATE353325T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT00909263T 1999-03-03 2000-02-28 4-heterocyclylsulfonamidyl-6-methoxy-5-(2-metho y-phenoxy)-2-pyridyl-pyrimidin derivate, deren herstellung und deren verwendung als endothelin rezeptor antagonisten ATE353325T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99104306 1999-03-03

Publications (1)

Publication Number Publication Date
ATE353325T1 true ATE353325T1 (de) 2007-02-15

Family

ID=8237697

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00909263T ATE353325T1 (de) 1999-03-03 2000-02-28 4-heterocyclylsulfonamidyl-6-methoxy-5-(2-metho y-phenoxy)-2-pyridyl-pyrimidin derivate, deren herstellung und deren verwendung als endothelin rezeptor antagonisten

Country Status (30)

Country Link
US (2) US6417360B1 (de)
EP (1) EP1185525B1 (de)
JP (1) JP3488203B2 (de)
KR (1) KR100478798B1 (de)
CN (1) CN1342158B (de)
AR (1) AR044720A1 (de)
AT (1) ATE353325T1 (de)
AU (1) AU756738B2 (de)
BR (1) BR0008717A (de)
CA (1) CA2364906C (de)
CY (1) CY1108002T1 (de)
CZ (1) CZ300324B6 (de)
DE (1) DE60033280T2 (de)
DK (1) DK1185525T3 (de)
ES (1) ES2280198T3 (de)
HK (1) HK1044943B (de)
HR (1) HRP20010630B1 (de)
HU (1) HUP0200080A3 (de)
ID (1) ID30484A (de)
IL (1) IL145051A0 (de)
MA (1) MA26776A1 (de)
NO (1) NO320809B1 (de)
NZ (1) NZ513671A (de)
PL (1) PL198815B1 (de)
PT (1) PT1185525E (de)
RS (1) RS50109B (de)
RU (1) RU2201928C1 (de)
TR (1) TR200102562T2 (de)
WO (1) WO2000052007A1 (de)
ZA (1) ZA200107157B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140724A (en) 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
US20020184047A1 (en) * 2001-04-03 2002-12-05 Plotnick Michael A. Universal ad queue
EP1454625A1 (de) * 2003-03-06 2004-09-08 Speedel Development AG Pyridylsulfonamidyl-pyrimidine zur Behandlung von diabetischen nephropathien
EP1595880A1 (de) * 2004-05-13 2005-11-16 Speedel Pharma AG Kristallforme eines Pyridinylsulfonamids und deren Verwendung als Endothelinrezeptorantagonisten
JP2009507890A (ja) * 2005-09-12 2009-02-26 シュペーデル・ファルマ・アーゲー 血管移植片機能不全の予防のためのピリジルスルホンアミジル−ピリミジン類
RU2435585C2 (ru) * 2006-04-13 2011-12-10 Актелион Фармасьютиклз Лтд Антагонисты рецептора эндотелина, предназначенные для ранней стадии идиопатического фиброза легких
EP1938812A1 (de) * 2006-12-22 2008-07-02 Speedel Pharma AG Pharmazeutische Zubereitung unter Verwendung von Aliskiren und Avosentan
US20100093758A1 (en) * 2008-07-23 2010-04-15 Auspex Pharmaceuticals, Inc. Pyridine sulfonamide modulators of endothelin-a receptor
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
KR101936054B1 (ko) 2017-06-23 2019-01-11 한국과학기술연구원 항염증 활성을 가지는 6-페녹시피리미딘 유도체, 이의 제조방법 및 이를 활성성분으로 하는 약학 조성물
TW202329952A (zh) 2021-12-17 2023-08-01 瑞士商愛杜西亞製藥有限公司 克拉生坦(clazosentan)二鈉鹽之製備方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2162630C (en) 1994-11-25 2007-05-01 Volker Breu Sulfonamides
CN1064965C (zh) * 1994-11-25 2001-04-25 弗·哈夫曼-拉罗切有限公司 新的磺酰胺类化合物及其作为药物的用途
US5837708A (en) 1994-11-25 1998-11-17 Hoffmann-La Roche Inc. Sulphonamides
TW313568B (de) * 1994-12-20 1997-08-21 Hoffmann La Roche
ATE267808T1 (de) 1997-08-19 2004-06-15 Hoffmann La Roche Verfahren zur herstellung von 2,5- disubstituierten pyridinen
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides

Also Published As

Publication number Publication date
HRP20010630A2 (en) 2002-08-31
US6417360B1 (en) 2002-07-09
DE60033280D1 (de) 2007-03-22
YU62801A (sh) 2004-07-15
CZ300324B6 (cs) 2009-04-22
ES2280198T3 (es) 2007-09-16
WO2000052007A1 (en) 2000-09-08
RU2201928C1 (ru) 2003-04-10
NO20014224D0 (no) 2001-08-31
JP2002538156A (ja) 2002-11-12
HK1044943B (zh) 2013-03-22
US20020137933A1 (en) 2002-09-26
EP1185525B1 (de) 2007-02-07
ZA200107157B (en) 2002-11-29
PT1185525E (pt) 2007-05-31
NO320809B1 (no) 2006-01-30
MA26776A1 (fr) 2004-12-20
CA2364906A1 (en) 2000-09-08
HK1044943A1 (de) 2002-11-08
DK1185525T3 (da) 2007-06-04
PL351794A1 (en) 2003-06-16
KR20010102480A (ko) 2001-11-15
RS50109B (sr) 2009-03-25
CA2364906C (en) 2006-01-10
AU3161100A (en) 2000-09-21
HUP0200080A2 (en) 2002-06-29
NZ513671A (en) 2003-04-29
ID30484A (id) 2001-12-13
DE60033280T2 (de) 2007-11-22
TR200102562T2 (tr) 2002-02-21
PL198815B1 (pl) 2008-07-31
EP1185525A1 (de) 2002-03-13
HRP20010630B1 (en) 2010-08-31
CZ20013108A3 (cs) 2002-02-13
JP3488203B2 (ja) 2004-01-19
KR100478798B1 (ko) 2005-03-24
CN1342158A (zh) 2002-03-27
AU756738B2 (en) 2003-01-23
NO20014224L (no) 2001-08-31
AR044720A1 (es) 2005-10-05
CN1342158B (zh) 2012-06-06
RU2001126348A (ru) 2004-03-20
CY1108002T1 (el) 2013-09-04
IL145051A0 (en) 2002-06-30
BR0008717A (pt) 2001-12-26
HUP0200080A3 (en) 2003-01-28
US6521631B2 (en) 2003-02-18

Similar Documents

Publication Publication Date Title
DE60113719D1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
DE60009116D1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DE50209483D1 (de) Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
DE60005386D1 (de) Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten
DE50312747D1 (de) Neue xanthinderivate, deren herstellung und deren verwendung als arzneimittel
DE50015711D1 (de) In 6-stellung substituierte indolinone, ihre herstellung und ihre verwendung als arzneimittel
DE69833223D1 (de) 4-aminothiazol derivate, deren herstellung und deren verwendung als inhibitoren cyclin-abhängiger kinasen
DE50312295D1 (de) 8-ä3-amino-piperidin-1-ylü -xanthine, deren herstellung und deren verwendung als arzneimittel
DE50213202D1 (de) Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
DE60015296D1 (de) Indolderivate und ihre verwendung als mcp-1 rezeptor antagonisten
ATE277905T1 (de) 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten
DE50112669D1 (de) Acridin-derivate und deren verwendung als arzneimittel
ATE255569T1 (de) Indeno-, naphtho- und benzocyclohepta- dihydrothiazol derivate, deren herstellung und deren verwendung als anorektische arzneimittel
ATE348805T1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
DE60127434D1 (de) Benzoxazinonderivative, deren herstellung und verwendung
ATE261959T1 (de) Substituierte phenyl-piperazin-derivate, deren herstellung und verwendung
DE50002417D1 (de) 3-Amino-3-arylpropan-1-ol-Derivate, deren Herstellung und Verwendung
ATE353325T1 (de) 4-heterocyclylsulfonamidyl-6-methoxy-5-(2-metho y-phenoxy)-2-pyridyl-pyrimidin derivate, deren herstellung und deren verwendung als endothelin rezeptor antagonisten
ATE329908T1 (de) Arylethene-sulfonamid derivate, deren herstellung und deren verwendung als endothelin-antagonisten
DE60005690D1 (de) Titanverbindungen, deren herstellung und verwendung
ATE254621T1 (de) Thienoisoxazolyl- und thienylpyrazolyl-phenoxy substituierte propyl derivate als d4 antagonisten
DE60126614D1 (de) 1,4-diazepan-2,5-dion-derivate und deren verwendung als nk-1 rezeptorantagonisten
ATE401333T1 (de) 1-oxa-3,9-diazaspiroc5.5üundecan-2-onderivate und deren verwendung als antagonisten des neurokininrezeptors
DE60002866D1 (de) Echinocandinderivate, deren herstellung und verwendung als fungizid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1185525

Country of ref document: EP